Columbia University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1754-01-01

Employees: 20.8K

Market Cap: -

Website: https://www.arch.columbia.edu

Clinical Trials

Awake Proning in COVID-19 Patients With Hypoxemic Respiratory Failure

Completed

Conditions: Coronavirus Infection
Oxygen Deficiency

Interventions: Other: Awake proning

First Posted Date: 2020-05-29

Last Posted Date: 2022-03-09

Lead Sponsor: Columbia University

Target Recruit Count: 29

Registration Number: NCT04408222

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

TXA127 for the Treatment of Severe COVID-19

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: TXA127
Drug: Placebo

First Posted Date: 2020-05-26

Last Posted Date: 2022-07-27

Lead Sponsor: Columbia University

Target Recruit Count: 22

Registration Number: NCT04401423

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism

Phase 1

Withdrawn

Conditions: NAFLD (Nonalcoholic Fatty Liver Disease)
NASH (Nonalcoholic Steatohepatitis)

Interventions: Drug: Placebo
Drug: PF-05221304

First Posted Date: 2020-05-20

Last Posted Date: 2021-08-25

Lead Sponsor: Columbia University

Registration Number: NCT04395950

Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection

Phase 2

Terminated

Conditions: COVID-19

Interventions: Other: Placebo
Drug: Clazakizumab

First Posted Date: 2020-05-08

Last Posted Date: 2022-04-08

Lead Sponsor: Columbia University

Target Recruit Count: 1

Registration Number: NCT04381052

Locations: 🇺🇸
Columbia University Medical Center / New York Presbyerian Hospital, New York, New York, United States

SUNLIGHT Study: Online Support Groups for MS to Address COVID-19

Not Applicable

Completed

Conditions: COVID-19
MS (Multiple Sclerosis)
Support Groups

Interventions: Behavioral: Online support Group

First Posted Date: 2020-05-07

Last Posted Date: 2021-01-08

Lead Sponsor: Columbia University

Target Recruit Count: 32

Registration Number: NCT04379661

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

Study of Rituximab or Tocilizumab for Patients with Steroid-Dependent Immune-Related Adverse Events (irAEs)

Phase 2

Recruiting

Conditions: Immune-related Adverse Events
Advanced Solid Tumor

Interventions: Drug: Tocilizumab
Drug: Rituximab

First Posted Date: 2020-05-05

Last Posted Date: 2024-12-16

Lead Sponsor: Columbia University

Target Recruit Count: 30

Registration Number: NCT04375228

Locations: 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, New York, New York, United States

Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19

Phase 4

Completed

Conditions: COVID-19
Venous Thromboses
Arterial Thrombosis

Interventions: Drug: Heparin Infusion
Drug: Enoxaparin Prophylactic Dose
Drug: Enoxaparin/Lovenox Intermediate Dose
Drug: Heparin SC

First Posted Date: 2020-04-29

Last Posted Date: 2024-12-10

Lead Sponsor: Columbia University

Target Recruit Count: 94

Registration Number: NCT04367831

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers

Recruiting

Conditions: Coronavirus
Covid-19
Coronavirus Infection

Interventions: Other: COVID-19 Serology
Behavioral: Health Care Worker Survey

First Posted Date: 2020-04-29

Last Posted Date: 2024-05-13

Lead Sponsor: Columbia University

Target Recruit Count: 1000

Registration Number: NCT04367857

Locations: 🇺🇸
NewYork-Presbyterian Hosptial/Columbia University Irving Medical Center, New York, New York, United States

Sildenafil for Treatment of Choroidal Ischemia

Phase 2

Active, not recruiting

Conditions: Vitelliform Macular Dystrophy
Age-related Macular Degeneration
Retinitis Pigmentosa
Central Serous Retinopathy
Choroidal Ischemia

Interventions: Other: Standard of Care Sildenafil
Drug: Sildenafil
Diagnostic Test: Ocular Coherence Tomography-Angiography (OCT-A)
Other: Visual Acuity (VA)

First Posted Date: 2020-04-22

Last Posted Date: 2023-10-23

Lead Sponsor: Columbia University

Target Recruit Count: 25

Registration Number: NCT04356716

Locations: 🇺🇸
Columbia University Medical Center, Edward Harkness Eye Institute, New York, New York, United States

Cerebrospinal Fluid Biomarkers in Bariatric Surgery

Not Applicable

Recruiting

Conditions: Obesity

Interventions: Procedure: Roux-en-Y Gastric Bypass (RYGB)
Procedure: Sleeve Gastrectomy (SG)
Behavioral: Very Low Calorie Diet (VLCD)

First Posted Date: 2020-04-17

Last Posted Date: 2024-04-01

Lead Sponsor: Columbia University

Target Recruit Count: 48

Registration Number: NCT04350892

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy